Clinical Trial Update: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating taselisib plus fulvestrant vs placebo plus fulvestrant in advanced/metastatic breast cancer with progression on/aromatase inhibitors; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Taselisib (GDC-0032)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-01-25